News articles for Resolve Therapeutics, LLC:
Wednesday, July 16, 2014
Resolve Initiates Phase 2 Clinical Study in SLE
SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE).
Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve ... read more